MedTrace Logo

Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis

NCT02426372 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2017-08-24

No results posted yet for this study

Summary

The purpose of this open-label, dose-ranging, exploratory study is to evaluate the safety, tolerability, compliance, mechanism of action and efficacy of QBECO site specific immunomodulation for the induction of clinical response and remission in subjects with moderate to severe ulcerative colitis

Conditions

Interventions

BIOLOGICAL

QBECO SSI

QBECO Site Specific Immunomodulators

Sponsors & Collaborators

  • Qu Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · Qu Biologics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02426372 on ClinicalTrials.gov